Profil
Charles A. McWherter worked as Vice President-Drug Discovery at Sugen, Inc. from 2001 to 2003.
From 2003 to 2007, served as VP & Head-Cardiovascular Therapeutics Areas at Pfizer Inc. Between 2007 and 2024, held the position of President-Research & Development at CymaBay Therapeutics, Inc. from 2022 to 2024.
In 2024 to 2025, was Independent Director at 89bio, Inc. Education includes a doctorate from Cornell University.
Anciens postes connus de Charles McWherter
| Sociétés | Poste | Fin |
|---|---|---|
| 89BIO, INC. | Directeur/Membre du Conseil | 30/10/2025 |
| CYMABAY THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 22/03/2024 |
| PFIZER INC. | Corporate Officer/Principal | 01/01/2007 |
Sugen, Inc.
Sugen, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs and related pharmaceutical products | Corporate Officer/Principal | 01/01/2003 |
Formation de Charles McWherter
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Sugen, Inc.
Sugen, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs and related pharmaceutical products | Health Technology |
CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for people with life-threatening diseases | Health Technology |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
89bio, Inc.
89bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
















